Riley, Ph.D., is the President and Co-founder of Riley and Rabel
Consulting Services, LLC. Dr. Riley received his bachelor’s degree in
pharmacy (1977) and Ph.D. degree in Pharmaceutical Chemistry (1980) from the
University of Bath, England. He was a post-doctoral fellow at the University
of Kansas in the Department of Pharmaceutical Chemistry (1981-1982) before
joining the faculty of the Department of Pharmaceutics at the University of
Florida. He returned to the University of Kansas as a faculty member in 1986
where he remained until 1994.
Dr. Riley’s industrial experience began in 1994 as head of Analytical R&D at Dupont Pharmaceuticals (previously Dupont Merck). In late 2001 he joined ALZA, a subsidiary of Johnson & Johnson, where he had positions of increasing responsibility up to Vice President and West Coast Site Head ChemPharm Development. He left ALZA in May 2007 to form Riley and Rabel Consulting Services. He has co-authored more than 100 book chapters and papers in peer-reviewed journals, as well as two books entitled Pharmaceutical and Biomedical Applications of Liquid Chromatography and Validation of Methods and Systems in Pharmaceutical and Biomedical Analysis. He was elected Fellow of the American Association of Pharmaceutical Scientists (AAPS) and served as the chair of the Analysis and Pharmaceutical Quality Section of AAPS and a Member of the AAPS Executive Committee. Dr. Riley has served as a member and chair of the PhRMA Analytical Technical Committee, as well as a member and chair of the PhRMA Technical Leadership Committee. Dr. Riley represented PhRMA on the ICH Expert Working Group on Impurities in Drug Substances (Q3A) and Drug Products (Q3B) and was Chair of the PhRMA Working Group on Genotoxic Impurities.
Rabel, Ph.D., is the Vice-President and Co-founder of Riley and Rabel
Consulting Services, LLC. Dr. Rabel received a B.S. in Chemistry from Northwest
Missouri State University in 1988. She then received a Ph.D. in Pharmaceutical
Chemistry from the University of Kansas in 1994, where she was awarded a USP
Fellowship and a Training Grant Fellowship with the National Cancer Institute.
Dr. Rabel has over 12 years of experience in the pharmaceutical industry. She started her career at DuPont Pharmaceutical Company (now Bristol-Myers Squibb) in the Basic Pharmaceutics and Biopharmaceutics group providing Preformulation/Formulation support for Discovery and Pharmaceutical Development groups. In 2002, Dr. Rabel joined ALZA Corporation, a subsidiary of Johnson & Johnson, as a Principal Scientist/Manager in Oral Products Development where she was responsible for the development of controlled-release dosage forms. In 2005, she accepted a position with Amgen, Inc. as Associate Director of Small Molecule Pharmaceutics at the San Francisco site. In this role she led the start up and integration of a new Pharmaceutics group, which provided Preformulation support for multiple projects and therapeutic areas. In May of 2007, Dr. Rabel co-founded Riley and Rabel Consulting Services, LLC. Dr. Rabel has nineteen publications, seventeen presentations, and three patents.